Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.
The phosphoinositide 3-kinase/AKT signaling pathway plays a key role in cancer cell growth, survival, and angiogenesis. Phosphoinositide-dependent protein kinase-1 (PDK1) acts at a focal point in this pathway immediately downstream of phosphoinositide 3-kinase and PTEN, where it phosphorylates numerous AGC kinases. The PDK1 kinase domain has at least three ligand-binding sites: the ATP-binding pocket, the peptide substrate-binding site, and a groove in the N-terminal lobe that binds the C-terminal hydrophobic motif of its kinase substrates. Based on the unique PDK1 substrate recognition system, ultrahigh throughput TR-FRET and Alphascreen screening assays were developed using a biotinylated version of the PDK1-tide substrate containing the activation loop of AKT fused to a pseudo-activated hydrophobic motif peptide. Using full-length PDK1, K(m) values were determined as 5.6 mum for ATP and 40 nm for the fusion peptide, revealing 50-fold higher affinity compared with the classical AKT(Thr-308)-tide. Kinetic and biophysical studies confirmed the PDK1 catalytic mechanism as a rapid equilibrium random bireactant reaction. Following an ultrahigh throughput screen of a large library, 2,000 compounds were selected from the reconfirmed hits by computational analysis with a focus on novel scaffolds. ATP-competitive hits were deconvoluted by dose-response studies at 1x and 10x K(m) concentrations of ATP, and specificity of binding was assessed in thermal shift assay. Inhibition studies using fusion PDK1-tide1 substrate versus AKT(Thr-308)-tide and kinase selectivity profiling revealed a novel selective alkaloid scaffold that evidently binds to the PDK1-interacting fragment pocket. Molecular modeling suggests a structural paradigm for the design of inhibitory versus activating allosteric ligands of PDK1.
Bobkova
Ekaterina V
EV
Merck Research Laboratories, Boston, Massachusetts 02115, USA. ebobkova@burnham.org
Weber
Michael J
MJ
Xu
Zangwei
Z
Zhang
Yan-Ling
YL
Jung
Joon
J
Blume-Jensen
Peter
P
Northrup
Alan
A
Kunapuli
Priya
P
Andersen
Jannik N
JN
Kariv
Ilona
I
D000255:Adenosine Triphosphate / Q000737:chemistry; D020816:Amino Acid Motifs; D000818:Animals; D001665:Binding Sites; D001703:Biophysics / Q000379:methods; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D031541:Fluorescence Resonance Energy Transfer; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D010455:Peptides / Q000737:chemistry; D011485:Protein Binding; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D015398:Signal Transduction
D004791:Enzyme Inhibitors; C000631429:PDK1 protein, human; D010455:Peptides; D000081382:Pyruvate Dehydrogenase Acetyl-Transferring Kinase; D000255:Adenosine Triphosphate; D017346:Protein Serine-Threonine Kinases
J Biomol Screen. 1999;4(2):67-73
10838414
Science. 2002 Dec 6;298(5600):1912-34
12471243
J Clin Oncol. 2008 Dec 10;26(35):5705-12
19001320
Biochemistry. 2005 Apr 5;44(13):5258-66
15794662
Nat Chem Biol. 2009 Oct;5(10):758-64
19718043
Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1272-7
17227859
EMBO J. 2006 Nov 29;25(23):5469-80
17110931
EMBO J. 2001 Aug 15;20(16):4380-90
11500365
Nat Protoc. 2007;2(9):2212-21
17853878
Structure. 2004 Feb;12(2):215-26
14962382
J Biol Chem. 2006 Aug 4;281(31):21670-21681
16737971
J Biol Chem. 2000 Jul 7;275(27):20806-13
10764742
J Biomol Screen. 2001 Dec;6(6):429-40
11788061
Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23
11934592
IUBMB Life. 2003 Mar;55(3):117-26
12822887
J Biol Chem. 1998 Jun 12;273(24):14845-52
9614086
Assay Drug Dev Technol. 2009 Feb;7(1):22-43
19382888
J Biomol Screen. 2009 Dec;14(10):1257-62
19822882
Nat Struct Biol. 1997 Apr;4(4):311-6
9095200
Biochem J. 2005 Jan 15;385(Pt 2):399-408
15456405
Semin Cell Dev Biol. 2004 Apr;15(2):161-70
15209375
Cell. 2006 Nov 3;127(3):635-48
17081983
Curr Biol. 1999 Apr 22;9(8):393-404
10226025
Ann Oncol. 2008 Mar;19(3):508-15
17998284
J Biol Chem. 2003 Apr 4;278(14):12406-14
12547827
Chem Biol Drug Des. 2009 Feb;73(2):179-88
19207420
EMBO J. 2000 Mar 1;19(5):979-88
10698939
J Biol Chem. 2000 Feb 25;275(8):5600-5
10681541
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7
18669648
J Chem Inf Model. 2008 Oct;48(10):2030-41
18831546
J Med Chem. 2009 Aug 13;52(15):4683-93
19606904
ChemMedChem. 2008 Dec;3(12):1810-38
18972468